548 related articles for article (PubMed ID: 26647767)
41. Mammary analogue secretory carcinoma of salivary glands: a new entity associated with ETV6 gene rearrangement.
Majewska H; Skálová A; Stodulski D; Klimková A; Steiner P; Stankiewicz C; Biernat W
Virchows Arch; 2015 Mar; 466(3):245-54. PubMed ID: 25503077
[TBL] [Abstract][Full Text] [Related]
42. Salivary Secretory Carcinoma Harboring a Novel ALK Fusion: Expanding the Molecular Characterization of Carcinomas Beyond the ETV6 Gene.
Sasaki E; Masago K; Fujita S; Suzuki H; Hanai N; Hosoda W
Am J Surg Pathol; 2020 Jul; 44(7):962-969. PubMed ID: 32205481
[TBL] [Abstract][Full Text] [Related]
43. A unique case of inflammatory myofibroblastic tumor of the liver manifesting with biloma: A case report.
Huang K; Zhao P; Zhao J; Zhao P; Yang J
Oncol Lett; 2022 Jul; 24(1):227. PubMed ID: 35720485
[TBL] [Abstract][Full Text] [Related]
44. Uterine inflammatory myofibroblastic tumor harboring novel NUDCD3-ROS1 and NRP2-ALK fusions: clinicopathologic features of 4 cases and literature review.
Zhang L; Luan L; Shen L; Xue R; Huang J; Su J; Huang Y; Xu Y; Wang X; Shao Y; Ji Y; Xu C; Hou Y
Virchows Arch; 2023 Mar; 482(3):567-580. PubMed ID: 36624188
[TBL] [Abstract][Full Text] [Related]
45. Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK.
Mariño-Enríquez A; Wang WL; Roy A; Lopez-Terrada D; Lazar AJ; Fletcher CD; Coffin CM; Hornick JL
Am J Surg Pathol; 2011 Jan; 35(1):135-44. PubMed ID: 21164297
[TBL] [Abstract][Full Text] [Related]
46. Identification of ROS1 rearrangement in gastric adenocarcinoma.
Lee J; Lee SE; Kang SY; Do IG; Lee S; Ha SY; Cho J; Kang WK; Jang J; Ou SH; Kim KM
Cancer; 2013 May; 119(9):1627-35. PubMed ID: 23400546
[TBL] [Abstract][Full Text] [Related]
47. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.
Kim MH; Shim HS; Kang DR; Jung JY; Lee CY; Kim DJ; Lee JG; Bae MK; Kim HR; Lim SM; Kim EY; Park JS; Chung KY; Kim HJ; Kim JH; Cho BC
Lung Cancer; 2014 Mar; 83(3):389-95. PubMed ID: 24462463
[TBL] [Abstract][Full Text] [Related]
48. A novel TPD52L2-ROS1 gene fusion expanding the molecular alterations in inflammatory myofibroblastic tumor: case report and literature review.
Liu X; Duan Y; Wang G; Zhu P
Diagn Pathol; 2023 Sep; 18(1):105. PubMed ID: 37735390
[TBL] [Abstract][Full Text] [Related]
49. Absence of human herpesvirus-8 and Epstein-Barr virus in inflammatory myofibroblastic tumor with anaplastic large cell lymphoma kinase fusion gene.
Yamamoto H; Kohashi K; Oda Y; Tamiya S; Takahashi Y; Kinoshita Y; Ishizawa S; Kubota M; Tsuneyoshi M
Pathol Int; 2006 Oct; 56(10):584-90. PubMed ID: 16984614
[TBL] [Abstract][Full Text] [Related]
50. Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma.
Montgomery EA; Shuster DD; Burkart AL; Esteban JM; Sgrignoli A; Elwood L; Vaughn DJ; Griffin CA; Epstein JI
Am J Surg Pathol; 2006 Dec; 30(12):1502-12. PubMed ID: 17122505
[TBL] [Abstract][Full Text] [Related]
51. An unusual fusion gene EML4-ALK in a patient with congenital mesoblastic nephroma.
Misove A; Vicha A; Zapotocky M; Malis J; Balko J; Nemeckova T; Szabova J; Kyncl M; Novakova-Kodetova D; Stolova L; Jencova P; Broz P; Krskova L
Genes Chromosomes Cancer; 2021 Dec; 60(12):837-840. PubMed ID: 34378283
[TBL] [Abstract][Full Text] [Related]
52. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.
Jurmeister P; Lenze D; Berg E; Mende S; Schäper F; Kellner U; Herbst H; Sers C; Budczies J; Dietel M; Hummel M; von Laffert M
Lung Cancer; 2015 Feb; 87(2):122-9. PubMed ID: 25534130
[TBL] [Abstract][Full Text] [Related]
53. Inflammatory myofibroblastic tumour of the urinary bladder: the role of immunoglobulin G4 and the comparison of two immunohistochemical antibodies and fluorescence in-situ hybridization for the detection of anaplastic lymphoma kinase alterations.
Choi E; Williamson SR; Montironi R; Zhang S; Wang M; Eble JN; Grignon DJ; Lopez-Beltran A; Idrees MT; Baldridge LA; Scarpelli M; Jones CL; Wang L; MacLennan GT; Osunkoya AO; Cheng L
Histopathology; 2015 Jul; 67(1):20-38. PubMed ID: 25406945
[TBL] [Abstract][Full Text] [Related]
54. ALK and ROS1 overexpression is very rare in colorectal adenocarcinoma.
Houang M; Toon CW; Clarkson A; Sioson L; de Silva K; Watson N; Singh NR; Chou A; Gill AJ
Appl Immunohistochem Mol Morphol; 2015 Feb; 23(2):134-8. PubMed ID: 24992173
[TBL] [Abstract][Full Text] [Related]
55. A novel ETV6-NTRK3 gene fusion in primary renal fibrosarcoma.
Jiang H
Eur Rev Med Pharmacol Sci; 2022 Jul; 26(13):4705-4708. PubMed ID: 35856362
[TBL] [Abstract][Full Text] [Related]
56. ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer.
Leeman-Neill RJ; Kelly LM; Liu P; Brenner AV; Little MP; Bogdanova TI; Evdokimova VN; Hatch M; Zurnadzy LY; Nikiforova MN; Yue NJ; Zhang M; Mabuchi K; Tronko MD; Nikiforov YE
Cancer; 2014 Mar; 120(6):799-807. PubMed ID: 24327398
[TBL] [Abstract][Full Text] [Related]
57. Histologic characterization of paediatric mesenchymal neoplasms treated with kinase-targeted therapy.
Baranov E; Winsnes K; O'Brien M; Voss SD; Church AJ; Janeway KA; DuBois SG; Davis JL; Al-Ibraheemi A
Histopathology; 2022 Aug; 81(2):215-227. PubMed ID: 35543076
[TBL] [Abstract][Full Text] [Related]
58. Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.
Wu J; Lin Y; He X; Yang H; He P; Fu X; Li G; Gu X
BMC Cancer; 2016 Aug; 16():599. PubMed ID: 27488371
[TBL] [Abstract][Full Text] [Related]
59. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases.
Yoshida A; Kohno T; Tsuta K; Wakai S; Arai Y; Shimada Y; Asamura H; Furuta K; Shibata T; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):554-62. PubMed ID: 23426121
[TBL] [Abstract][Full Text] [Related]
60. Partial Response to Ceritinib in a Patient With Abdominal Inflammatory Myofibroblastic Tumor Carrying a TFG-ROS1 Fusion.
Li Y; Chen X; Qu Y; Fan JM; Li Y; Peng H; Zheng Y; Zhang Y; Zhang HB
J Natl Compr Canc Netw; 2019 Dec; 17(12):1459-1462. PubMed ID: 31805529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
